Work

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps11570

Authors: Matthew Ingham, Jacob B Allred, Katherine Gano, Suzanne George, Steven Attia, Melissa Amber Burgess, Sosipatros Alexandros Boikos, Nam Bui, James Lin Chen, Julia Lee Close, Mahesh Seetharam, Premal H. Thaker, Gary K. Schwartz

Institutions: Columbia University Irving Medical Center, Mayo Clinic, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Florida, UPMC Hillman Cancer Center, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, Stanford Cancer Institute, The Ohio State University, University of Florida, Mayo Clinic in Arizona, Washington University in St. Louis

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Conquer Cancer Foundation, National Institutes of Health

OpenAlex ID: W3029957756

Cites:

Cited by: 6

Related to: 10